Free Trial Information
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

Flagship Pioneering Gene Writing company Tessera Therapeutics Inc. raised a $230 million series B round co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures and SoftBank Vision Fund 2i, with participation from Qatar Investment...
Read More
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

Several inflammatory and cancer indications will soon see human proof-of-concept data from small molecules targeting the kinase IRAK4, as a class of at least eight such molecules makes its way through early-stage trials. IRAK4 mediates innate...
Read More
BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

...launches with $62M A round, pipeline of antibody-TLR9...
...are antibodies conjugated to T-CpG, the company’s targeted TLR9...
...– Toll-like receptor 8TLR9 – Toll-like receptor 9 Sandi Wong Toll-like receptor 9 (TLR9) Cancer Cancer...
Read More
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

Three more biotechs gained value in the aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback and Sigilon each rose by double digits. With the trio’s listings, more...
Read More
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
Read More
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
Read More
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

Zai prices Hong Kong offering, becomes dual-listedCross-border in-licensing company Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) raised HK$5.9 billion ($776.1 million) via an offering that will land it on the Hong Kong stock exchange. The deal’s combined...
Read More
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...$15 midpoint of its proposed range. The cancer company’s lead program contains a CpG-A oligonucleotide TLR9...
...billion ($1.4 billion) in an offering that gives it a dual listing. Targets TLR9 - Toll-like receptor 9 Paul...
Read More
BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

...TriSalus’ pivot into therapeutics development. TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9...
...into the tumor to deliver full efficacy,” Szela told BioCentury. She said that with Dynavax’s TLR9...
...$0.85 (10%) to $8.96 on Monday. Targets TLR9 -- Toll-like receptor 9 Virginia Li, Associate Editor Dynavax Technologies Corp. Toll-like receptor 9 (TLR9) TriSalus...
Read More
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...be valued at roughly $325 million. The cancer company’s lead program contains a CpG-A oligonucleotide TLR9...
...monotherapy and in combination with Opdivo nivolumab to treat refractory melanoma (see “New Indications for TLR9...
...sell 5 million shares at $14-$16. Targets IRAK4 - Interleukin-1 receptor-associated kinase 4 TLR9 - Toll-like receptor 9 Paul...
Read More
Items per page:
1 - 10 of 1278